Frankfurt
24.01.25
08:07 Uhr
1,932 Euro
-0,098
-4,83 %
-4,83 %
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,972 | 2,035 | 22:20 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12.24 | Crossject confirms ZEPIZURE supply chain readiness with another successful ISO audit for Quality Management System | 60 | GlobeNewswire (Europe) | Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France)Company is ramping up supply chain to prepare for commercialization in U.S. Dijon, France, December 19, 2024... ► Artikel lesen | |
| 11.12.24 | Crossject announces the pricing of its reserved capital increase and warrants issuance for an aggregate amount of EUR 7.2M | 2 | GlobeNewswire (USA) | ||
| 10.12.24 | Crossject launches reserved capital increase and warrants issuance for an aggregate amount of at least €7m | 1 | GlobeNewswire (USA) | ||
| 09.12.24 | Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement | 1 | GlobeNewswire (USA) | ||
| 13.11.24 | Crossject's ZENEO Auto-Injector's usability further demonstrated in extreme HAZMAT conditions | 1 | GlobeNewswire (USA) | ||
| 22.10.24 | Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE ahead of filing U.S. Emergency Use Authorization | 100 | GlobeNewswire (Europe) | Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file... ► Artikel lesen | |
| CROSSJECT Aktie jetzt für 0€ handeln | |||||
| 26.09.24 | Crossject announces its eligibility for France's PEA-PME investment scheme | 1 | GlobeNewswire (USA) | ||
| 23.09.24 | Crossject reports financial results and business highlights for the first six months of 2024 | 203 | GlobeNewswire (Europe) | Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file for the... ► Artikel lesen | |
| 17.09.24 | Crossject to report first-half 2024 financial results and host webcast on September 23, 2024 | 1 | GlobeNewswire (USA) | ||
| 22.08.24 | Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024 | 1 | GlobeNewswire (USA) | ||
| 19.08.24 | Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE Epilepsy Rescue Treatment | 204 | GlobeNewswire (Europe) | Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment Experienced executive to lead preparations... ► Artikel lesen | |
| 18.07.24 | Crossject achieves key ZEPIZURE manufacturing milestone | 144 | GlobeNewswire (Europe) | Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is... ► Artikel lesen | |
| 10.07.24 | Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO Epinephrine | 166 | GlobeNewswire (Europe) | Key contribution to the acceleration of the development of ZENEO® EpinephrineFinancial support includes mainly grants, as well as subsidized loansFrance 2030 Plan dedicated to supporting French companies... ► Artikel lesen | |
| 26.06.24 | Crossject elaborates on ZEPIZURE potential in light of landmark RAMPART study and its own, recently published, bioequivalence study | 200 | GlobeNewswire (Europe) | Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine... ► Artikel lesen | |
| 12.06.24 | Crossject appoints Dan Chiche, MD as Chief Medical Officer North America | 216 | GlobeNewswire (Europe) | Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical productsReinforces leadership team and expands presence in North AmericaSupports processes... ► Artikel lesen | |
| 14.05.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.05.2024 | 682 | Xetra Newsboard | Das Instrument 3W1 SE0000236382 CONCEJO AB (PUBL) B SK 5 EQUITY wird ex Kapitalmassnahme gehandelt am 14.05.2024 The instrument 3W1 SE0000236382 CONCEJO AB (PUBL) B SK 5 EQUITY is traded ex capital... ► Artikel lesen | |
| 25.04.24 | Crossject reports audited financial results for 2023 | 203 | GlobeNewswire (Europe) | Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free... ► Artikel lesen | |
| 08.04.24 | XFRA 74C: WIEDERAUFNAHME/RESUMPTION | 239 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 02.04.24 | Crossject advances in its U.S. Strategy and reports Financial Results for 2023 | 288 | GlobeNewswire (Europe) | Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDAExpectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE®... ► Artikel lesen | |
| 02.04.24 | XFRA 74C: AUSSETZUNG/SUSPENSION | 148 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCROSSJECT SA EO... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 36,720 | -0,22 % | Leichte Zugewinne bei der Fresenius SE & Co. KGaA-Aktie (36,58 €) | Das Wertpapier von Fresenius SE & Co. KGaA notiert heute fester. Der jüngste Kurs betrug 36,58 Euro. Die Fresenius+Co KgaA-Aktie verzeichnet gegenwärtig einen Wertanstieg von 2,75 Prozent. Sie hat sich... ► Artikel lesen | |
| INTUITIVE SURGICAL | 557,50 | -4,49 % | Soll ich diese Aktien jetzt kaufen? Intel, Intuitive Surgical und UnitedHealth im Check | Soll ich diese Aktien jetzt kaufen? Intel, Intuitive Surgical und UnitedHealth im Chec ► Artikel lesen | |
| SERNOVA | 0,133 | +0,68 % | Sernova (TSE:SVA) Sets New 12-Month Low - Here's What Happened | ||
| VITA 34 | 4,080 | -1,45 % | Original-Research: Vita 34 AG (von Montega AG): Vita 34 AG | Original-Research: Vita 34 AG - von Montega AG 27.11.2024 / 10:10 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group AG. Für den Inhalt der Mitteilung... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,640 | 0,00 % | Geratherm Medical Aktie: Fortschritte führen zum Erfolg! | Die Geratherm Medical AG, ein Spezialist für medizinische Temperaturmesstechnik, verzeichnet einen vielversprechenden Jahresbeginn 2025. Der Aktienkurs des Unternehmens stieg am 17. Januar auf 3,68... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 222,00 | -1,60 % | The Analyst Verdict: Align Tech In The Eyes Of 3 Experts | ||
| NUGEN MEDICAL DEVICES | 0,050 | +10,62 % | Unglaubliche News! Der Super-CEO der alle Türen öffnen kann! | ||
| PLUS THERAPEUTICS | 1,170 | +1,56 % | Plus Therapeutics Announces Renewal Of Master Services Agreement With Telix | CANBERA (dpa-AFX) - Plus Therapeutics (PSTV) announced the renewal of its Master Services Agreement with Telix IsoTherapeutics Group. The MSA secures supply of cGMP Re-186, the radioisotope... ► Artikel lesen | |
| CARDINAL HEALTH | 123,15 | -0,81 % | Dividendenbekanntmachungen (15.01.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,59 USD 0,5723 EUR ABBVIE INC US00287Y1091 1,64 USD 1,591 EUR ABBVIE INC CDR CA00288K1084 0... ► Artikel lesen | |
| RESMED | 236,00 | -1,26 % | ResMed-Aktie: Kurs nur geringfügig im Minus (235,7531 €) | Der Kurs der dem Anteilsschein von ResMed kommt kaum von der Stelle. Der jüngste Kurs betrug 245,36 US-Dollar. Kaum auffällig ist zur Stunde an der Börse der Kurs von ResMed. Das Wertpapier liegt mit... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,906 | 0,00 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 | SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment... ► Artikel lesen | |
| DAVITA | 161,70 | -0,83 % | DaVita stock soars to all-time high of $169.54 amid robust growth | ||
| MEDICLIN | 3,060 | +6,99 % | EQS-Adhoc: MEDICLIN AG: MEDICLIN hebt Jahresprognose für das Geschäftsjahr 2024 an | EQS-Ad-hoc: MEDICLIN AG / Schlagwort(e): Prognoseänderung/Jahresergebnis
MEDICLIN hebt Jahresprognose für das Geschäftsjahr 2024 an
21.01.2025 / 15:05 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| UNIDOC HEALTH | 0,300 | +1,35 % | UniDoc - Unternehmen verbucht erste Umsätze nach Auslieferung von mit KI ausgestatteten H3 Health Cubes | - Drei Kunden nahmen Zustellung zum Jahresende entgegen
VANCOUVER, British Columbia, 9. Januar 2025 / IRW-Press / UniDoc Health Corp. (CSE: UDOC) (FWB: L7T) (OTCQB: UDOCF) ("UniDoc"... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen |
Das Unternehmen CROSSJECT SA kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 1,932 Euro und damit -4,83 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CROSSJECT SA finden Sie auf Wallstreet Online.
